> 首页 > 产品 > 一抗 > 基因重组 > Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab)

Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab)

Recombinant Antibody

Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab) is 97.02%, determined by SEC-HPLC.
Immobilized human CD22 His at 2 ug/mL can bind Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab), EC50=0.008601 ug/mL.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P20273
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	146 KDa

Additional Information
Target/Specificity	Siglec-2 / CD22
Endotoxin	< 0.001EU/ µg,determined by LAL method.
Conjugation	Unconjugated
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.